Meta-analysis of 5,445 patients found semaglutide produced greater weight loss than liraglutide (-6.08 kg difference) and dulaglutide in type 2 diabetes, but tirzepatide outperformed semaglutide by 3.78 kg.
6.08 kg more weight lossSemaglutide produced significantly more weight loss than liraglutide in T2DM patients — but tirzepatide outperformed semaglutide by another 3.78 kg
What the researchers found
Semaglutide showed significantly greater weight loss than liraglutide (mean difference -6.08 kg, 95% CI -8.40 to -3.75) in T2DM patients, while tirzepatide produced significantly greater weight loss than semaglutide (mean difference -3.78 kg, 95% CI -5.52 to -2.04).
Why it matters
With multiple GLP-1 drugs available, patients and doctors need evidence-based guidance on which produces the most weight loss. This meta-analysis provides the clearest head-to-head comparison yet, helping inform treatment choices for the millions of people with type 2 diabetes who need weight management.
The numbers in context
Meta-analysis pooled data from multiple direct comparison trials of semaglutide versus other GLP-1 RAs in T2DM patients.
How the study worked
Systematic review and meta-analysis following PRISMA guidelines. PubMed, Embase, and Cochrane Library were searched for studies comparing semaglutide with other GLP-1 RAs for weight loss in T2DM patients. Nine studies with 5,445 patients (mean age 60, mean follow-up 32.5 weeks) were included. Meta-analysis used SPSS version 29.
Who was studied
Adults with type 2 diabetes mellitus
What this study cannot tell us
Limited to 9 studies — few direct head-to-head trials exist. Mean follow-up of only 32.5 weeks may not capture long-term weight loss differences. The semaglutide vs. dulaglutide comparison didn't reach statistical significance. Different study designs and patient populations across included trials may introduce heterogeneity. Tirzepatide is technically a dual GIP/GLP-1 agonist, not a pure GLP-1 RA.
How to read the evidence
Moderate-to-strong evidence from a systematic review and meta-analysis of 9 comparative studies. Limited by the small number of head-to-head trials and relatively short follow-up periods.
When this study was published
Published in 2024, providing an up-to-date comparison that includes tirzepatide alongside established GLP-1 drugs.
The bigger picture
The GLP-1 drug landscape is rapidly evolving. This meta-analysis confirms the hierarchy among GLP-1 drugs for weight loss in diabetes: tirzepatide > semaglutide > dulaglutide/liraglutide > exenatide. As even newer multi-agonist drugs (survodutide, retatrutide) enter clinical trials, this ranking will likely continue to evolve. The key message is that not all GLP-1 drugs are equal for weight loss.
Questions still open
- Do the weight loss differences between GLP-1 drugs persist beyond 32 weeks of treatment?
- Should the superior weight loss with tirzepatide make it the first-line choice over semaglutide in T2DM patients needing weight management?
- How will emerging triple-agonists like retatrutide compare to the current GLP-1 drug hierarchy?
Common questions
Which GLP-1 drug produces the most weight loss for type 2 diabetes?
Are the side effects different between these GLP-1 drugs?
Read the original research
Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
Cureus, 16(9), e69008
Citation
Wen, Jimmy; Nadora, Denise; Bernstein, Ethan; How-Volkman, Christiane; Truong, Alina; Akhtar, Muzammil; Prakash, Neha A; Puglisi, Jose; Frezza, Eldo. (2024). Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.. Cureus, 16(9), e69008. https://doi.org/10.7759/cureus.69008